Akebia Therapeutics Inc (NAS:AKBA)

$ 1.705 0.08 (4.91%) Market Cap: 358.54 Mil Enterprise Value: 352.78 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q2 2024 Akebia Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$1.19 (+7.21%)

Earnings
Akebia Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Akebia Therapeutics Inc Earnings Call Transcript
Nov 08, 2023

$0.96 (-11.93%)

Earnings
Q2 2023 Akebia Therapeutics Inc Earnings Call Transcript
Aug 25, 2023

$1.15 (-8.00%)

Earnings
Akebia Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Akebia Therapeutics Inc To Discuss The Response To The FDRR Transcript
May 30, 2023
Q1 2023 Akebia Therapeutics Inc Earnings Call Transcript
May 08, 2023

$1.06 (-2.75%)

Earnings
Akebia Therapeutics Inc to Host Stockholder Information Session Transcript
Apr 21, 2023
Q4 2022 Akebia Therapeutics Inc Earnings Call Transcript
Mar 09, 2023

$0.8007 (-22.26%)

Earnings
Q3 2022 Akebia Therapeutics Inc Earnings Call Transcript
Nov 03, 2022

$0.2851 (+7.34%)

Earnings
Q2 2022 Akebia Therapeutics Inc Earnings Call Transcript
Aug 04, 2022

$0.41 (+4.99%)

Earnings
Q1 2022 Akebia Therapeutics Inc Earnings Call Transcript
May 09, 2022

$0.3454 (-10.26%)

Earnings
Akebia Therapeutics Inc Corporate Call Transcript
Mar 30, 2022
Akebia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Q3 2021 Akebia Therapeutics Inc Earnings Call Transcript
Nov 09, 2021

$2.86 (-0.35%)

Earnings
Akebia Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 27, 2021
Akebia Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Akebia Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

$2.87 (+15.73%)

Earnings
Akebia Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 02, 2021
Q1 2021 Akebia Therapeutics Inc Earnings Call Transcript
May 10, 2021

$2.9 (-7.05%)

Earnings
Q4 2020 Akebia Therapeutics Inc Earnings Call Transcript
Feb 25, 2021

$3.47 (-18.93%)

Earnings
Akebia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Akebia Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

$2.49 (-3.11%)

Earnings
Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined Transcript
Oct 23, 2020
Akebia Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Akebia Therapeutics Inc Conference Call and Live Webcast to Discuss the PRO(2)TECT Data Transcript
Sep 03, 2020
Akebia Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
Q1 2020 Akebia Therapeutics Inc Earnings Call Transcript
May 05, 2020

$11.95 (+37.99%)

Earnings
Q4 2019 Akebia Therapeutics Inc Earnings Call Transcript
Mar 10, 2020

$7.43 (-7.70%)

Earnings
Akebia Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Akebia Therapeutics Inc Earnings Call Transcript
Nov 12, 2019

$3.33 (-9.02%)

Earnings
Akebia Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q2 2019 Akebia Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

$4.17 (+13.93%)

Earnings
Q1 2019 Akebia Therapeutics Inc Earnings Call Transcript
May 09, 2019

$5.92 (+0.51%)

Earnings
Q4 2018 Akebia Therapeutics Inc Earnings Call Transcript
Mar 18, 2019

Earnings

Akebia Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2020 / 12:00PM GMT

Release Date Price: $11.31 (+1.25%)

Transcript

Michael Yee

Jefferies, LLC - Analyst

Good morning, everyone. Welcome to the 2020 Jefferies Healthcare Conference. I am Michael Yee, a managing director at Jefferies on the biotech team. Kicking us off this morning I am very happy to have the CEO of Akebia Therapeutics, John Butler, on with us.

Obviously John recently announced some very positive data for his new drug, Vadadustat. And without further ado I will turn it over to John who will give you an update on the story and all of the plans for Akebia. So, John, take it away.

John Butler

Akebia Therapeutics, Inc. - President & CEO

Mike thanks so much, really appreciate the opportunity to come and speak to you today about Akebia. Just reminding everyone that we're going to be making forward-looking statements today, so please refer to our SEC filings for more information.

It really is an incredibly exciting time at Akebia right now. Akebia is a fully integrated biopharma company focused on delivering therapeutic options to better the life of each person impacted by kidney disease.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.